Arsenic-protein interactions as a mechanism of arsenic toxicity.


Journal

Toxicology and applied pharmacology
ISSN: 1096-0333
Titre abrégé: Toxicol Appl Pharmacol
Pays: United States
ID NLM: 0416575

Informations de publication

Date de publication:
15 11 2021
Historique:
received: 23 07 2021
revised: 28 09 2021
accepted: 30 09 2021
pubmed: 8 10 2021
medline: 31 12 2021
entrez: 7 10 2021
Statut: ppublish

Résumé

Millions of people worldwide are exposed to arsenic, a metalloid listed as one of the top chemical pollutants of concern to human health. Epidemiological and experimental studies link arsenic exposure to the development of cancer and other diseases. Several mechanisms have been proposed to explain the effects induced by arsenic. Notably, arsenic and its metabolites interact with proteins by direct binding to individual cysteine residues, cysteine clusters, zinc finger motifs, and RING finger domains. Consequently, arsenic interactions with proteins disrupt the functions of proteins and may lead to the development and progression of diseases. In this review, we focus on current evidence in the literature that implicates the interaction of arsenic with proteins as a mechanism of arsenic toxicity. Data show that arsenic-protein interactions affect multiple cellular processes and alter epigenetic regulation, cause endocrine disruption, inhibit DNA damage repair mechanisms, and deregulate gene expression, among other adverse effects.

Identifiants

pubmed: 34619159
pii: S0041-008X(21)00342-2
doi: 10.1016/j.taap.2021.115738
pii:
doi:

Substances chimiques

Arsenicals 0
Endocrine Disruptors 0
Environmental Pollutants 0
Proteins 0
Cysteine K848JZ4886

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

115738

Informations de copyright

Copyright © 2021 Elsevier Inc. All rights reserved.

Auteurs

Cristian A Vergara-Gerónimo (CA)

Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México (UNAM), Ciudad Universitaria, Apartado Postal 70228, Ciudad de México, Mexico.

Alfonso León Del Río (A)

Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México (UNAM), Ciudad Universitaria, Apartado Postal 70228, Ciudad de México, Mexico.

Mauricio Rodríguez-Dorantes (M)

Instituto Nacional de Medicina Genómica, Ciudad de México, Mexico.

Patricia Ostrosky-Wegman (P)

Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México (UNAM), Ciudad Universitaria, Apartado Postal 70228, Ciudad de México, Mexico.

Ana María Salazar (AM)

Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México (UNAM), Ciudad Universitaria, Apartado Postal 70228, Ciudad de México, Mexico. Electronic address: anamsm@biomedicas.unam.mx.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH